FDA has granted priority review to naloxone nasal spray (Indivior) for the treatment of opioid overdose. If approved, naloxone nasal spray is expected to be the first FDA-approved intranasal naloxone product indicated to treat opioid overdose in the United States.
FDA has granted priority review to naloxone nasal spray (Indivior) for the treatment of opioid overdose. If approved, naloxone nasal spray is expected to be the first FDA-approved intranasal naloxone product indicated to treat opioid overdose in the United States.
Related: Naloxone dispensing, education for pharmacists available in new guide from CPNP
Naloxone nasal spray is designed to deliver naloxone through the nasal mucosa of an overdose victim. The drug comes as a pre-filled device that contains naloxone specially formulated for optimal absorption into the nasal mucosa. The device has been designed to require minimal training so individuals may be better equipped to help an opioid overdose victim.
“Naloxone is the standard treatment for an opioid overdose,” according to Shaun Thaxter, chief executive officer of Indivior. “Naloxone works as an opioid receptor antagonist that effectively binds to the opioid receptors in the brain and reverses the effects of natural and synthetic opioids. Currently, only needle-based formulations of naloxone are FDA-approved for emergency medical professionals. However, [this] naloxone nasal spray is designed to enable anyone-be they layperson, trained healthcare personnel or first responders-to administer treatment at the scene of an overdose.
In April 2014, FDA approved Evzio (naloxone hydrochloride injection, Kaléo) that can be used by family members or caregivers to treat a person known or suspected to have had an opioid overdose. The drug rapidly delivers a single dose of the drug naloxone via a hand-held auto-injector that can be carried in a pocket or stored in a medicine cabinet. It is intended for the emergency treatment of known or suspected opioid overdose, characterized by decreased breathing or heart rates, or loss of consciousness.
Related: [BLOG]: Use and abuse of opioids: FDA responds
There are 3 take-aways formulary managers need to remember when it comes to naloxone, according to Thaxter:
As drug abuse has reached epidemic proportions in the United States, formulary managers should be aware of the following 3 issues:
Read next: Florida passes naloxone law
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More